Company Profile
Board of Directors
Fuminori Yoshida Representative Director and President
Chief Executive OfficerDetails
Kazuo Asakawa Representative Director and Executive Vice President
Chief Commercial Officer
Head of the Japan Business UnitDetails
Shigetoshi Matsumoto Board Director<Outside>Details
George Morstyn Board Director<Outside>Details
Milton Grannatt Board Director<Outside>Details
Robin D. Campbell Board Director<Outside>Details
Kiyoshi Watanabe Full-Time Audit & Supervisory Board Member<Outside>Details
Saneaki Ichijo Audit & Supervisory Board Member<Outside>Details
Kesao Endo Audit & Supervisory Board Member<Outside>Details
Fuminori Yoshida
Representative Director and President
Chief Executive Officer
Fuminori Yoshida established SymBio Pharmaceuticals Limited, his third company, in March of 2005 in order to address the unmet medical needs of Japanese patients; as founding President of two other major healthcare companies, Nippon BioRad Laboratories (1980) and Amgen Japan (1993), he has earned high visibility and credibility within Japan's healthcare and academic communities. Following his graduation from Gakushuin University in 1971 with a B.S. in Organic Chemistry, he went on to receive an M.S. in Molecular Biology from MIT (1973) and M.S. in Health Policy and Management from Harvard University Graduate School (1975). He possesses dual experience and expertise in the management of major Japanese and American corporations through his work for various companies in the past, such as Mitsubishi Corporation and AHS Japan, Syntex Japan (1993) as President and CEO, serving concurrently at Amgen Japan (presently, Takeda Bio Development Center Ltd.) as President and CEO, and Amgen Inc. as Corporate Vice-President for 12 years until January of 2005. He has retained a high profile within the pharmaceutical industry due to his active involvement in various conferences (e.g. keynote speaker at 1st Bio-Expo), as member of several committees sponsored by the Ministry of Science and Technology, as lecturer at several prestigious colleges (e.g. Waseda University), as author of various publications in reputable pharmaceutical business journals, and as author of two books which were subsequently published in Japan (‘Golden DNA Helix' and ‘A Story of a Biotech Pioneer'). Utilizing his extensive management experience and social network, he has assembled an exceptional management team at SymBio.
Kazuo Asakawa Kazuo Asakawa
Representative Director and Executive Vice President
Chief Commercial Officer
Head of the Japan Business Unit
Kazuo Asakawa graduated from the Faculty of Engineering, Chiba Institute of Technology, in 1977, and subsequently completed a Master's degree in Industrial Chemistry at the Graduate School of Engineering of the university, and then joined Sandoz Japan K.K. He successively held various important positions such as General Manager, Central Nervous System Unit, Nippon Roche K.K. (1994), Group Manager, Special Products Group, Sandoz Japan K.K. (1997), General Manager, Marketing Department, Novartis Pharma K.K. (1997), Corporate Officer, Head of Transplantation & Immunology Business Division, Novartis Pharma K.K. (2002), and Managing Director, Head of Oncology Business Unit, Novartis Pharma K.K. (2005).
He joined SymBio Pharmaceuticals Limited in December 2015 as Head of the Japan Business Unit of the Company, and assumed the position of Corporate Officer, Executive Vice President; Chief Operating Officer and Head of the Japan Business Unit of the Company in March 2016. He became Representative Director of the Company in March 2017, and currently serves as Representative Director, Executive Vice President; Chief Commercial Officer and Head of the Japan Business Unit.
Motoshi Matsumoto Shigetoshi Matsumoto
Board Director<Outside>
Shigetoshi Matsumoto graduated from University of Toyama Faculty of Pharmacy and Pharmaceutical Sciences in 1972, and then joined CHUGAI PHARMACEUTICAL CO., LTD. After holding various positions in Sales & Marketing related divisions, he assumed the position of General Manager of the Audit Office (2002),
At the Company, he has successively held the positions of Full-time Audit & Supervisory Board Member (2007), and Senior Advisor (2011). He became Advisor to APO PLUS STATION Co., Ltd. in 2011, and then became Senior Advisor to Protiviti LLC in 2015. He served as a member of the Audit & Supervisory Board at the Company in 2017.
He currently serves as Audit Practice Counselor, Japan Audit & Supervisory Board Members Association.
George Morstyn George Morstyn
Board Director<Outside>
Former Senior Vice-President of Development and CMO, Amgen Inc. Dr. Morstyn, an outstanding scholar in oncogenetics, was a pioneer in the clinical trial development of hematopoietic growth factors. During his tenure at Amgen, many drug products received marketing approval by US FDA and were subsequently launched. After returning to Australia, he was appointed to the Board of Directors of Bionomics Limited, Glykoz Pty Limited, and the Royal Women's Hospital in Melbourne. He has also held appointments as a Director of several Australian companies, including, Chairman GBS Venture Capital firm, Deputy Chairman Victorian Comprehensive Cancer Centre. He is Currently chief executive officer of G & R Morstyn Pty Ltd., and, a Director of the Co-operative Research Centre for Cancer Therapeutics, Biomedvic and Actinogen Medical Ltd. In 2013 was elected a fellow of ATSE (The Australian Academy of Technological Sciences and Engineering).
Milton Grannatt Milton Grannatt
Board Director<Outside>
Milton Grannatt earned his Ph.D. in Economics at Lehigh University, Bethlehem, Pennsylvania, and previously served as Vice President of Global Business Development at Novartis Pharmaceuticals Corp., and Vice President of Finance and Strategic Development at Sterling Winthrop, Inc. He brings to SymBio more than 24 years of experience and success working at global healthcare companies in business development, mergers & acquisitions, and finance. He is now serving on the Advisory Boards of VOX Telehealth and Biohealthonimics, a lecturer at Princeton's Evergreen Forum, and a member of the Board of Governors of the Certified Licensing Professionals.
Robin D. Campbell Robin D. Campbell
Board Director<Outside>
Dr. Campbell earned his Ph.D. in Microbiology and Immunology at Wake Forest University School of Medicine in 1984. He started his pharmaceutical career at Ciba Geigy Pharmaceuticals in 1984, and joined Amgen Inc. in 1989. While at Amgen, he held several positions of increasing responsibility, including Senior Director of Product Development and Vice President and General Manager of the U.S. Oncology Business Unit. From 2004 to 2008, he was President and CEO of Naryx Pharma. He is currently the Executive Chairman of Aptitude Medical Systems, a private research platform technology company, and serves on the Board of Directors of Pfenex, Inc., a U.S.-based public biopharmaceutical company. Dr. Campbell lectures on business strategy and marketing in the Technology Management Program at the University of California, Santa Barbara.
Kiyoshi Watanabe Kiyoshi Watanabe
Full-Time Audit & Supervisory Board Member<Outside>
Kiyoshi Watanabe graduated from Hitotsubashi University Faculty of Commerce and Management in 1974, and then joined The Industrial Bank of Japan, Limited (currently Mizuho Bank, Ltd.). He completed a Master's degree (MSM) at Purdue University Krannert School of Management. After serving as Chief of The Americas Corporate Credit Office, Credit Department of the Bank from 1998 in New York, he joined Kyowa Hakko Kogyo Co., Ltd. in 2003 as General Manager, Corporate Planning Office. He became General Manager, Medicine Planning Department of the Company in 2005, and then became General Manager, Planning and Administration Department at KYOWA HAKKO BIO CO., LTD. in 2008. He assumed the position of Full-time Audit & Supervisory Board Member at Kawaguchi Chemical Industry Co., Ltd. in 2011, and currently serves as Member of the Audit & Supervisory Board at Toho Acetylene Co., Ltd., a position he has held since 2015.
Saneaki Ichijo Saneaki Ichijo
Audit & Supervisory Board Member<Outside>
Saneaki Ichijo graduated from the Faculty of Law, Chuo University, in 1968, and subsequently completed a Master's degree in law at New York University. He received his certification as a lawyer (Daiichi Tokyo Bar Association) in 1973, and later joined Anderson Mori and Rabinowitz (currently Anderson Mori and Tomotsune) to present.
Kesao Endo Kesao Endo
Audit & Supervisory Board Member<Outside>
Kesao Endo received his certification as a Certified Public Accountant in 1983. He joined Price Waterhouse Consultant in 1984. He joined Deloitte and Touche in 1986 and was stationed at Deloitte's Los Angeles and New York offices. He earned his USPCA (United States Certified Public Accountant) in 1991. He currently serves as a member of the Audit & Supervisory Board at Akebono Brake Industry Co., Ltd., and outside director of Careerlink Co., Ltd. and is a partner of ABS Audit Corporation.